Product Information
ADALIMUMAB-ADAZ(CF) PEN 40 MG/0.4 ML is a generic product labeled by Sandoz Inc., priced at $1587.8176 per ML under NDC 61314032720. Its NADAC has been published 116 times since Jul 17, 2024.
Strength
40 mg/.4mL
Manufacturer
Sandoz Inc.NDC
61314032720
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
ADALIMUMABApproval Type
Biologic (BLA)
FDA Application
BLA761071On Market Since
7/1/2023
Pharmacological Classes
Price Statistics
The NADAC for ADALIMUMAB-ADAZ(CF) PEN 40 MG/0.4 ML has been published 116 times since Jul 17, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $1587.8176 per ML |
|---|---|
| All-time high | $1593.6406 (Mar 11, 2026) |
| All-time low | $1586.7323 (Aug 19, 2026) |
| 52-week high | $1593.6406 |
| 52-week low | $1586.7323 |
| Median price | $1591.7581 |
| Average price | $1590.7366 |
| Largest weekly change | -0.2% (Aug 21, 2024) |
| Weeks tracked | 116 |
| Tracking since | Jul 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the adalimumab-adaz market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sandoz Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
adalimumab-adaz market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Tumor Necrosis Factor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ADALIMUMAB-ADAZ(CF) PEN 40 MG/0.4 ML?
The current National Average Drug Acquisition Cost (NADAC) for ADALIMUMAB-ADAZ(CF) PEN 40 MG/0.4 ML, manufactured by Sandoz Inc., is $1587.8176 per ML (NDC 61314032720), effective Sep 30, 2026.
How has the price of ADALIMUMAB-ADAZ(CF) PEN 40 MG/0.4 ML changed over time?
Over the history we have for it, the NADAC for ADALIMUMAB-ADAZ(CF) PEN 40 MG/0.4 ML has held within roughly two percent of its current level. It has been tracked across 116 weekly CMS publications since Jul 17, 2024.
What are the highest and lowest recorded NADAC prices for ADALIMUMAB-ADAZ(CF) PEN 40 MG/0.4 ML?
Since Jul 17, 2024, the NADAC for ADALIMUMAB-ADAZ(CF) PEN 40 MG/0.4 ML has ranged from a low of $1586.7323 (Aug 19, 2026) to a high of $1593.6406 (Mar 11, 2026), with a median of $1591.7581 per ML.
Are there cheaper alternatives to ADALIMUMAB-ADAZ(CF) PEN 40 MG/0.4 ML?
No other NADAC-published product currently shares the active ingredient and strength of ADALIMUMAB-ADAZ(CF) PEN 40 MG/0.4 ML in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ADALIMUMAB-ADAZ(CF) PEN 40 MG/0.4 ML?
ADALIMUMAB-ADAZ(CF) PEN 40 MG/0.4 ML (NDC 61314032720) is labeled by Sandoz Inc., and CMS classifies it as a generic product.